These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38457191)

  • 41. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
    Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
    Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
    Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
    J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin.
    Liang X; Liu Q; Yao W; Yang S
    Medicine (Baltimore); 2022 Dec; 101(49):e31187. PubMed ID: 36626436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
    Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.
    Lin S; Lu JJ; Han L; Chen Q; Pan J
    BMC Cancer; 2010 Feb; 10():39. PubMed ID: 20146823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
    Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
    Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
    Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
    Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Du C; Ying H; Zhou J; Hu C; Zhang Y
    Int J Clin Oncol; 2013 Jun; 18(3):464-71. PubMed ID: 22527846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up.
    Wang L; Miao J; Huang H; Chen B; Xiao X; Zhu M; Liang Y; Xiao W; Huang S; Peng Y; Deng X; Lv X; Xia W; Xiang Y; Guo X; Han F; Zhao C
    Cancer Res Treat; 2022 Jan; 54(1):118-129. PubMed ID: 34098625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Niu X; Hu C; Kong L
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.
    Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
    Chin J Cancer; 2013 Oct; 32(10):525-32. PubMed ID: 24016394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma].
    Liu KQ; Jin F; Jiang H; Wu WL; Li YY; Long JH; Luo XL; Gong XY; Chen XX; Liu LN; Gan JY; Zhou JJ
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):133-138. PubMed ID: 32135648
    [No Abstract]   [Full Text] [Related]  

  • 55. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.
    Liao S; Zhang B; Su Y; Pan Y; Zhang J; Ye Z; Zhang R; Kong X; Qin G; Mo Y; Ruan X; Liu J; Gan C; Dai J; Zhang R; Luo G; Liao X; Jiang W
    Strahlenther Onkol; 2024 Oct; 200(10):867-875. PubMed ID: 38324078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
    Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Au KH; Ngan RKC; Ng AWY; Poon DMC; Ng WT; Yuen KT; Lee VHF; Tung SY; Chan ATC; Sze HCK; Cheng ACK; Lee AWM; Kwong DLW; Tam AHP
    Oral Oncol; 2018 Feb; 77():16-21. PubMed ID: 29362121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.